# AstraZeneca investment in Summit Therapeutics

> Live situation record from CLSTR: https://clstr.news/situations/astrazeneca-investment-in-summit-therapeutics
> Updated: 2026-10-04T16:58:07.000Z. Sources: 19. Developments: 2.

AstraZeneca has initiated a $2 billion strategic equity investment in Summit Therapeutics through the purchase of convertible preferred stock. This deal is intended to accelerate the development of the investigational PD-1/VEGF bispecific antibody, ivonescimab.

Following the investment, a collaboration was established between Summit Therapeutics, AstraZeneca, and Daiichi Sankyo to conduct a Phase III clinical trial. This study will evaluate the combination of Datroway and ivonescimab for patients with first-line triple-negative breast cancer. While the companies will share trial costs, each will retain the development and commercial rights to their respective medicines.

## Timeline

### 2026-10-04: AstraZeneca invests $2 billion in Summit Therapeutics for cancer drug trials

AstraZeneca has completed a $2 billion investment in Summit Therapeutics and partnered with Daiichi Sankyo for a Phase III trial of ivonescimab in triple-negative breast cancer.

3 sources. https://clstr.news/cluster/astrazeneca-invests-2-billion-in-summit-therapeutics-for-cancer-drug-trials

### 2026-09-29: AstraZeneca announces $2bn Summit Therapeutics deal and Italian research investment

AstraZeneca is investing $2 billion in Summit Therapeutics for a cancer drug collaboration and launching a 66.2 million euro research program in Italy over the next three years.

16 sources. https://clstr.news/cluster/astrazeneca-invests-2-billion-in-summit-therapeutics-for-cancer-drug-research

---
Cite as: AstraZeneca investment in Summit Therapeutics. CLSTR, https://clstr.news/situations/astrazeneca-investment-in-summit-therapeutics